Analysts warn that China's edge in fast, cost-effective early clinical trials, which has propelled its emergence as a global biopharmaceutical powerhouse, is at risk. US lawmakers and Food and Drug Administration (FDA) officials have raised concerns about American pharmaceutical companies' increasing reliance on conducting early clinical trials in China, citing process opaqueness and the need to maintain medical oversight.